The stock of Concordia International Corp (NASDAQ:CXRX) is a huge mover today! About 718,074 shares traded hands. Concordia International Corp (NASDAQ:CXRX) has declined 88.38% since March 11, 2016 and is downtrending. It has underperformed by 93.84% the S&P500.
The move comes after 5 months negative chart setup for the $206.10 million company. It was reported on Oct, 14 by Barchart.com. We have $3.41 PT which if reached, will make NASDAQ:CXRX worth $24.73M less.
Analysts await Concordia International Corp (NASDAQ:CXRX) to report earnings on November, 10. They expect $1.35 EPS, up 3.05% or $0.04 from last year’s $1.31 per share. CXRX’s profit will be $71.90 million for 0.72 P/E if the $1.35 EPS becomes a reality. After $1.21 actual EPS reported by Concordia International Corp for the previous quarter, Wall Street now forecasts 11.57% EPS growth.
Concordia International Corp (NASDAQ:CXRX) Ratings Coverage
Out of 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Concordia Healthcare Corp. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. Goldman Sachs initiated it with “Neutral” rating and $32 target price in Monday, June 6 report. The firm has “Hold” rating by TD Securities given on Thursday, August 4. RBC Capital Markets reinitiated the shares of CXRX in a report on Thursday, October 1 with “Outperform” rating. The firm earned “Sector Perform” rating on Monday, September 19 by Scotia Capital. The stock of Concordia International Corp (NASDAQ:CXRX) earned “Neutral” rating by Goldman Sachs on Monday, August 15. The rating was downgraded by GMP Securities to “Hold” on Monday, August 15. Laurentian maintained the shares of CXRX in a report on Tuesday, March 29 with “Buy” rating. The firm has “Sector Outperform” rating given on Tuesday, September 29 by Scotia Capital. On Monday, August 15 the stock rating was downgraded by IBC to “Underperformer”. Canaccord Genuity maintained it with “Buy” rating and $95 target price in Tuesday, August 11 report.
According to Zacks Investment Research, “Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada.”
More recent Concordia International Corp (NASDAQ:CXRX) news were published by: Business.Financialpost.com which released: “Concordia International Corp takeover unlikely â€“ Goldman” on September 27, 2016. Also Business.Financialpost.com published the news titled: “Concordia International Corp stock crashes on proposed U.K. legislation over …” on September 16, 2016. Fool.ca‘s news article titled: “Concordia International Corp.: A Safe Buy?” with publication date: October 10, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.